Werewolf Therapeutics (HOWL) eyes 2026 catalysts following FDA guidance and encouraging INDUKINE results

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) is included on our list of stocks under $1 that will explode. On December 18, 2025, ...
Investing

Evnin Luke sells Werewolf Therapeutics (HOWL) stock for $117k

Director Luke Evnin reported selling shares of Werewolf Therapeutics Inc (NASDAQ:HOWL) between December 2nd and December 4th, 2025. The sales, executed under a prearranged 10b5-1 trading plan, totaled ...
Seeking Alpha

Werewolf Therapeutics: Still In The Race To Develop Next Generation Cytokines

HOWL reported interim data in November from its phase 1/1b trial of WTX-124 in solid tumors. There are signs of antitumor activity at the 12 mg dose of WTX-124, with two unconfirmed partial responses ...
Yahoo Finance

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Werewolf Therapeutics, Inc. (HOWL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
Nasdaq

Werewolf (HOWL) Up on Deal With Merck for Solid Tumor Study

Werewolf Therapeutics, Inc. HOWL announced that it has entered into a collaboration and supply agreement with pharma giant Merck MRK to evaluate its lead pipeline candidate, WTX-124, in combination ...